PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
25363799-0	2015	The phytocannabinoid, Delta9-tetrahydrocannabivarin, can act through 5-HT1A receptors to produce antipsychotic effects.	phytocannabinoid	4-20	5-hydroxytryptamine receptor 1A	Rattus norvegicus	69-75
33347604-0	2021	Phytocannabinoid-dependent mTORC1 regulation is dependent upon IPMK activity.	phytocannabinoid	0-16	CREB regulated transcription coactivator 1	Mus musculus	27-33
34758399-5	2021	The signaling of D9-THCA and D9-THCV via, individual receptors or receptor heteromers disclosed differential bias, i.e. the bias for, a given phytocannabinoid depended on the receptor (CB1, CB2 or CB1-CB2) and on, the compound used as reference to calculate the bias factor (D9-THC, a selective, agonist or a non-selective agonist).	phytocannabinoid	142-158	centromere protein X	Homo sapiens	17-24
34758399-5	2021	The signaling of D9-THCA and D9-THCV via, individual receptors or receptor heteromers disclosed differential bias, i.e. the bias for, a given phytocannabinoid depended on the receptor (CB1, CB2 or CB1-CB2) and on, the compound used as reference to calculate the bias factor (D9-THC, a selective, agonist or a non-selective agonist).	phytocannabinoid	142-158	cannabinoid receptor 1	Homo sapiens	185-188
34758399-5	2021	The signaling of D9-THCA and D9-THCV via, individual receptors or receptor heteromers disclosed differential bias, i.e. the bias for, a given phytocannabinoid depended on the receptor (CB1, CB2 or CB1-CB2) and on, the compound used as reference to calculate the bias factor (D9-THC, a selective, agonist or a non-selective agonist).	phytocannabinoid	142-158	cannabinoid receptor 2	Homo sapiens	190-193
34758399-5	2021	The signaling of D9-THCA and D9-THCV via, individual receptors or receptor heteromers disclosed differential bias, i.e. the bias for, a given phytocannabinoid depended on the receptor (CB1, CB2 or CB1-CB2) and on, the compound used as reference to calculate the bias factor (D9-THC, a selective, agonist or a non-selective agonist).	phytocannabinoid	142-158	cannabinoid receptor 1	Homo sapiens	197-204
34218397-12	2021	This phytocannabinoid also partially reversed LPS-evoked IL-6 increase in both the hypothalamus and hippocampus.	phytocannabinoid	5-21	interleukin 6	Homo sapiens	57-61
33347604-0	2021	Phytocannabinoid-dependent mTORC1 regulation is dependent upon IPMK activity.	phytocannabinoid	0-16	inositol polyphosphate multikinase	Homo sapiens	63-67
33998887-11	2021	Conclusion: Administration of the phytocannabinoid Delta9THC promotes significant recovery from TBI and is associated with upregulation of brain G-CSF, BDNF, and GDNF, neurotrophic factors previously shown to mediate brain self-repair following TBI and stroke.	phytocannabinoid	34-50	colony stimulating factor 3 (granulocyte)	Mus musculus	145-150
33998887-11	2021	Conclusion: Administration of the phytocannabinoid Delta9THC promotes significant recovery from TBI and is associated with upregulation of brain G-CSF, BDNF, and GDNF, neurotrophic factors previously shown to mediate brain self-repair following TBI and stroke.	phytocannabinoid	34-50	brain derived neurotrophic factor	Mus musculus	152-156
33998887-11	2021	Conclusion: Administration of the phytocannabinoid Delta9THC promotes significant recovery from TBI and is associated with upregulation of brain G-CSF, BDNF, and GDNF, neurotrophic factors previously shown to mediate brain self-repair following TBI and stroke.	phytocannabinoid	34-50	glial cell line derived neurotrophic factor	Mus musculus	162-166
33510643-5	2020	Treatment with the phytocannabinoid cannabidiol and the transient receptor potential vanilloid-1 (TRPV-1) channel antagonist capsazepine diminished LID intensity and decreased TNF-alpha levels without impacting other inflammation markers.	phytocannabinoid	19-35	tumor necrosis factor	Mus musculus	176-185
32863231-5	2020	The phytocannabinoid cannabidiol (CBD) inhibits BACH1 but lacks significant NRF2 activating properties.	phytocannabinoid	4-20	BTB domain and CNC homolog 1	Homo sapiens	48-53
33001012-1	2021	9 -Tetrahydrocannabinol ( 9 -THC), the active phytocannabinoid in cannabis, is virtually an adjunct to the endogenous endocannabinoid signaling system.	phytocannabinoid	46-62	WASP actin nucleation promoting factor	Homo sapiens	29-32
32360362-4	2020	Peripubertal treatment with the non-euphoric phytocannabinoid cannabidiol (30 mg/kg) from postnatal day (PND) 19 to PND 39 was able to reverse in MAM exposed rats: i) the up-regulation of the dopamine D3 receptor mRNA (only partially prevented by haloperidol 0.6 mg/kg/day); and ii) the regional blood flow changes in MAM exposed rats.	phytocannabinoid	45-61	dopamine receptor D3	Rattus norvegicus	192-212
32510591-1	2020	BACKGROUND AND PURPOSE: Delta9 -THCA-A, the precursor of Delta9 -THC, is a non-psychotropic phytocannabinoid that shows PPARgamma agonistic activity.	phytocannabinoid	92-108	peroxisome proliferator activated receptor gamma	Mus musculus	120-129
32904155-1	2020	Background: The insulin-sensitizing phytocannabinoid, Delta(9)-tetrahydrocannabivarin (THCV) can signal partly via G-protein coupled receptor-55 (GPR55 behaving as either an agonist or an antagonist depending on the assay).	phytocannabinoid	36-52	G protein-coupled receptor 55	Mus musculus	115-144
32904155-1	2020	Background: The insulin-sensitizing phytocannabinoid, Delta(9)-tetrahydrocannabivarin (THCV) can signal partly via G-protein coupled receptor-55 (GPR55 behaving as either an agonist or an antagonist depending on the assay).	phytocannabinoid	36-52	G protein-coupled receptor 55	Mus musculus	146-151
32751516-6	2020	Using the current dataset, meaningful models for CB1 and CB2 receptor agonism were obtained, and these reveal the insignificant relationships between the major phytocannabinoid content and receptor affinity for CB1 but good correlations between the two at CB2 receptors.	phytocannabinoid	160-176	cannabinoid receptor 1	Homo sapiens	49-52
32751516-6	2020	Using the current dataset, meaningful models for CB1 and CB2 receptor agonism were obtained, and these reveal the insignificant relationships between the major phytocannabinoid content and receptor affinity for CB1 but good correlations between the two at CB2 receptors.	phytocannabinoid	160-176	cannabinoid receptor 2	Homo sapiens	57-60
31892132-5	2019	Therefore, we investigated the effect of beta-caryophyllene (BCP), a CB2-selective phytocannabinoid, in a model of NRTI-induced neuropathic pain.	phytocannabinoid	83-99	cannabinoid receptor 2 (macrophage)	Mus musculus	69-72
32374168-1	2020	Cannabidiol (CBD), a phytocannabinoid, has been reported to have anti-inflammatory effects associated with NLRP3 inflammasome activation, but its mechanism of anti-inflammasome action remains unclear.	phytocannabinoid	21-37	NLR family pyrin domain containing 3	Homo sapiens	107-112
32374168-7	2020	CBD inhibitory effects on the NLRP3 inflammasome may contribute to the overall anti-inflammatory effects reported for this phytocannabinoid.	phytocannabinoid	123-139	NLR family pyrin domain containing 3	Homo sapiens	30-35
32457622-6	2020	Exogenously, GPR12 is a target for the phytocannabinoid cannabidiol (CBD).	phytocannabinoid	39-55	G protein-coupled receptor 12	Homo sapiens	13-18
31110286-4	2019	Here, we test the central hypothesis that liver-type fatty acid binding protein (FABP1) mediates phytocannabinoid transport and subsequent inactivation.	phytocannabinoid	97-113	fatty acid binding protein 1, liver	Mus musculus	42-79
31529613-1	2019	(-)-Cannabidiol ((-)-CBD), a non-psychoactive phytocannabinoid from Cannabis, and its structural analogs have received growing attention in recent years because of their potential therapeutic benefits, including neuroprotective, anti-epileptic, anti-inflammatory, anxiolytic, anti-cancer properties.	phytocannabinoid	46-62	opsin 1, medium wave sensitive	Homo sapiens	21-24
30738036-2	2019	The molecular mechanism is not well defined but the beneficial effects of this phytocannabinoid are blocked by antagonists of both cannabinoid CB2 (CB2R) and serotonin 5-HT1A (5-HT1AR) receptors that, in addition, may form heteromers in a heterologous expression system.	phytocannabinoid	79-95	cannabinoid receptor 2	Rattus norvegicus	143-146
30738036-2	2019	The molecular mechanism is not well defined but the beneficial effects of this phytocannabinoid are blocked by antagonists of both cannabinoid CB2 (CB2R) and serotonin 5-HT1A (5-HT1AR) receptors that, in addition, may form heteromers in a heterologous expression system.	phytocannabinoid	79-95	cannabinoid receptor 2	Rattus norvegicus	148-152
30738036-2	2019	The molecular mechanism is not well defined but the beneficial effects of this phytocannabinoid are blocked by antagonists of both cannabinoid CB2 (CB2R) and serotonin 5-HT1A (5-HT1AR) receptors that, in addition, may form heteromers in a heterologous expression system.	phytocannabinoid	79-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	168-174
30738036-2	2019	The molecular mechanism is not well defined but the beneficial effects of this phytocannabinoid are blocked by antagonists of both cannabinoid CB2 (CB2R) and serotonin 5-HT1A (5-HT1AR) receptors that, in addition, may form heteromers in a heterologous expression system.	phytocannabinoid	79-95	5-hydroxytryptamine receptor 1A	Rattus norvegicus	176-183
31110286-4	2019	Here, we test the central hypothesis that liver-type fatty acid binding protein (FABP1) mediates phytocannabinoid transport and subsequent inactivation.	phytocannabinoid	97-113	fatty acid binding protein 1, liver	Mus musculus	81-86
29941868-5	2019	Using beta-arrestin2 recruitment and cAMP accumulation assays, we recently found that the nonpsychoactive phytocannabinoid cannabidiol (CBD) is an inverse agonist for GPR3, GPR6, and GPR12.	phytocannabinoid	106-122	arrestin beta 2	Homo sapiens	6-20
31097982-1	2019	The nonpsychoactive phytocannabinoid, CBD, was recently approved by the Food and Drug Administration for the treatment of children with drug-resistant epilepsy.	phytocannabinoid	20-36	opsin 1, medium wave sensitive	Homo sapiens	38-41
29941868-5	2019	Using beta-arrestin2 recruitment and cAMP accumulation assays, we recently found that the nonpsychoactive phytocannabinoid cannabidiol (CBD) is an inverse agonist for GPR3, GPR6, and GPR12.	phytocannabinoid	106-122	G protein-coupled receptor 3	Homo sapiens	167-171
29941868-5	2019	Using beta-arrestin2 recruitment and cAMP accumulation assays, we recently found that the nonpsychoactive phytocannabinoid cannabidiol (CBD) is an inverse agonist for GPR3, GPR6, and GPR12.	phytocannabinoid	106-122	G protein-coupled receptor 6	Homo sapiens	173-177
29941868-5	2019	Using beta-arrestin2 recruitment and cAMP accumulation assays, we recently found that the nonpsychoactive phytocannabinoid cannabidiol (CBD) is an inverse agonist for GPR3, GPR6, and GPR12.	phytocannabinoid	106-122	G protein-coupled receptor 12	Homo sapiens	183-188
29977202-6	2018	The phytocannabinoid modulated signaling mediated by receptors and receptor heteromers even at low concentrations of 0.1-1 muM.	phytocannabinoid	4-20	latexin	Homo sapiens	123-126
30343038-1	2019	Beta-caryophyllene (BCP) is a phytocannabinoid possessing selective agonistic activity to cannabinoid type-2 receptors (CB2R) and peroxisome proliferator-activated receptors-alpha (PPAR-alpha).	phytocannabinoid	30-46	peroxisome proliferator activated receptor alpha	Rattus norvegicus	181-191
28888984-4	2017	Our data demonstrate that cannabidiol (CBD), a major non-psychoactive phytocannabinoid, acted as an inverse agonist to inhibit cAMP accumulation stimulated by the constitutively active GPR12.	phytocannabinoid	70-86	G protein-coupled receptor 12	Homo sapiens	185-190
27471947-6	2017	The phytocannabinoid cannabidiol (CBD) possesses neuroprotective, antioxidant and anti-inflammatory properties and reduces amyloid-beta production and tau hyperphosphorylation in vitro.	phytocannabinoid	4-20	amyloid beta precursor protein	Homo sapiens	123-135
27471947-6	2017	The phytocannabinoid cannabidiol (CBD) possesses neuroprotective, antioxidant and anti-inflammatory properties and reduces amyloid-beta production and tau hyperphosphorylation in vitro.	phytocannabinoid	4-20	microtubule associated protein tau	Homo sapiens	151-154
28368293-0	2017	(-)-beta-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis.	phytocannabinoid	49-65	cannabinoid receptor 2 (macrophage)	Mus musculus	26-29
28368293-1	2017	(-)-beta-caryophyllene (BCP), a cannabinoid receptor type 2 (CB2)-selective phytocannabinoid, has already been shown in precedent literature to exhibit both anti-inflammatory and analgesic effects in mouse models of inflammatory and neuropathic pain.	phytocannabinoid	76-92	cannabinoid receptor 2 (macrophage)	Mus musculus	61-64
27851727-1	2016	The human cannabinoid G-protein-coupled receptors (GPCRs) CB1 and CB2 mediate the functional responses to the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG) and to the widely consumed plant phytocannabinoid Delta9-tetrahydrocannabinol (THC).	phytocannabinoid	205-221	cannabinoid receptor 1	Homo sapiens	58-61
27851727-1	2016	The human cannabinoid G-protein-coupled receptors (GPCRs) CB1 and CB2 mediate the functional responses to the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG) and to the widely consumed plant phytocannabinoid Delta9-tetrahydrocannabinol (THC).	phytocannabinoid	205-221	cannabinoid receptor 2	Homo sapiens	66-69
27696789-6	2016	BCP is a phytocannabinoid with strong affinity to cannabinoid receptor type 2 (CB2 ), but not cannabinoid receptor type 1 (CB1 ).	phytocannabinoid	9-25	opsin 1, short wave sensitive	Homo sapiens	0-3
27696789-6	2016	BCP is a phytocannabinoid with strong affinity to cannabinoid receptor type 2 (CB2 ), but not cannabinoid receptor type 1 (CB1 ).	phytocannabinoid	9-25	cannabinoid receptor 2	Homo sapiens	79-82
26361728-0	2015	Repeated administration of phytocannabinoid Delta(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.	phytocannabinoid	27-43	cannabinoid receptor 1 (brain)	Mus musculus	187-190
23933222-2	2013	The aim of this study was to examine the influence of short-term (1-2 hours) exposure to cannabidiol, a major phytocannabinoid, on human placental breast cancer resistance protein function.	phytocannabinoid	110-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	147-179
25069049-6	2014	ICAM-1-dependent pro-killing effects were further confirmed for the phytocannabinoid Delta(9)-tetrahydrocannabinol (THC) and R(+)-methanandamide (MA), a hydrolysis-stable endocannabinoid analogue.	phytocannabinoid	68-84	intercellular adhesion molecule 1	Homo sapiens	0-6
24210682-0	2014	The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain.	phytocannabinoid	39-55	cannabinoid receptor 2 (macrophage)	Mus musculus	16-19
26054900-2	2015	The major psychoactive phytocannabinoid found in cannabis  (9)-tetrahydrocannabinol (THC) produces the majority of its pharmacological effects through two cannabinoid receptors, termed CB1 and CB2.	phytocannabinoid	23-39	cannabinoid receptor 1	Homo sapiens	185-188
26054900-2	2015	The major psychoactive phytocannabinoid found in cannabis  (9)-tetrahydrocannabinol (THC) produces the majority of its pharmacological effects through two cannabinoid receptors, termed CB1 and CB2.	phytocannabinoid	23-39	cannabinoid receptor 2	Homo sapiens	193-196
21821735-0	2011	Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.	phytocannabinoid	21-37	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	74-80
23621789-1	2013	In previous studies, compound 1 (AM411), a 3-(1-adamantyl) analogue of the phytocannabinoid (-)-Delta(8)-tetrahydrocannabinol (Delta(8)-THC), was shown to have improved affinity and selectivity for the CB1 receptor.	phytocannabinoid	75-91	cannabinoid receptor 1	Rattus norvegicus	202-205
23924692-0	2013	Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.	phytocannabinoid	38-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
24204703-4	2013	As CBD is a non-psychoactive phytocannabinoid that appears to be devoid of side effects, our results support its exploitation as an effective anti-cancer drug in the management of gliomas.	phytocannabinoid	29-45	opsin 1, medium wave sensitive	Homo sapiens	3-6
22300105-1	2012	BACKGROUND AND PURPOSE: Cannabichromene (CBC) is a major non-psychotropic phytocannabinoid that inhibits endocannabinoid inactivation and activates the transient receptor potential ankyrin-1 (TRPA1).	phytocannabinoid	74-90	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	152-190
22300105-1	2012	BACKGROUND AND PURPOSE: Cannabichromene (CBC) is a major non-psychotropic phytocannabinoid that inhibits endocannabinoid inactivation and activates the transient receptor potential ankyrin-1 (TRPA1).	phytocannabinoid	74-90	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	192-197
19819240-1	2009	The phytocannabinoid Delta(9)-Tetrahydrocannabinol (Delta(9)-THC), the main psychoactive cannabinoid in cannabis, activates a number of signalling cascades including p53.	phytocannabinoid	4-20	transformation related protein 53, pseudogene	Mus musculus	166-169
21215722-6	2011	The CB1/CB2-OT column was also used to screen a botanical matrix, Zanthoxylum clava-herculis, where preliminary results suggest the presence of a high-affinity phytocannabinoid.	phytocannabinoid	160-176	cannabinoid receptor 1	Homo sapiens	4-7
21215722-6	2011	The CB1/CB2-OT column was also used to screen a botanical matrix, Zanthoxylum clava-herculis, where preliminary results suggest the presence of a high-affinity phytocannabinoid.	phytocannabinoid	160-176	cannabinoid receptor 2	Homo sapiens	8-11
20196794-1	2010	PURPOSE: We assessed the anticonvulsant potential of the phytocannabinoid Delta9-tetrahydrocannabivarin (Delta9-THCV) by investigating its effects in an in vitro piriform cortex (PC) brain slice model of epileptiform activity, on cannabinoid CB1 receptor radioligand-binding assays and in a generalized seizure model in rats.	phytocannabinoid	57-73	cannabinoid receptor 1	Rattus norvegicus	242-245
19096514-7	2009	The same was observed with the transient receptor potential vanilloid type 1 (TRPV1) antagonist capsazepine and with cannabidiol, a nonpsychotomimetic phytocannabinoid that produces anxiolytic-like effects after systemic administration in humans and laboratory animals.	phytocannabinoid	151-167	transient receptor potential cation channel subfamily V member 1	Homo sapiens	31-76
17876300-3	2007	GPR55 was activated by a range of plant, synthetic and endogenous cannabinoids and blocked by the non-psychoactive phytocannabinoid, cannabidiol.	phytocannabinoid	115-131	G protein-coupled receptor 55	Mus musculus	0-5
19285060-8	2009	The aim of the present study was to investigate whether another pharmacologically active phytocannabinoid, cannabidiol, similarly activates PPARgamma.	phytocannabinoid	89-105	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	140-149